#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC

Kyle LaHucik

Senior Reporter

CHICAGO — In its “first time on a bigger stage” at this weekend’s ASCO conference, Cullinan Oncology thinks it has the data to “distinguish itself” …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

#AS­CO22: With me­di­an dura­bil­i­ty da­ta, Cul­li­nan aims to 'dis­tin­guish it­self' from Takeda's Exkiv­i­ty and J&J's Ry­bre­vant in ex­on 20 NSCLC

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC